Abstract
Strontium ranelate exerts both an anticatabolic and an anabolic effect on bone cells. To further investigate the mechanism by which strontium ranelate inhibits bone resorption, the effects of varying concentrations of Sro2+ on osteoclastic differentiation were studied using RAW 264.7 cells and peripheral blood monocytic cells (PBMCs). We report that increasing concentrations of Sro2+ down-regulate osteoclastic differentiation and tartrate-resistant acid phosphatase activity, leading to inhibition of bone resorption (−48% when PBMCs were cultured for 14 days in the presence of 2 mM Sro2+). Using a dominant-negative form of the calcium-sensing receptor (CaR) and a small interfering RNA approach, we provide evidences that the inhibition of osteoclast differentiation by Sro2+ is mediated by stimulation of the CaR. Moreover, our results suggest that the effects of Sro2+ on osteoclasts are, at least in part, mediated by inhibition of the receptor activator of nuclear factor-κB ligand (RANKL)-induced nuclear translocation of nuclear factor-κB and activator protein-1 in the early stages of osteoclastic differentiation. In conclusion, our data indicate that Sr2+ directly inhibits the formation of mature osteoclasts through down-regulation of RANKL-induced osteoclast differentiation and decreases osteoclast differentiation through the activation of the CaR.
Footnotes
↵ The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.
This work was supported by the Institut de Recherches Internationales Servier [Grant PHA-12911-141-FRA/001].
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
doi:10.1124/mol.109.063347.
-
ABBREVIATIONS:
- Sro2+
- extracellular concentration of Sr2+
- α-MEM
- α-modified minimum essential medium
- PBMC
- peripheral blood mononuclear cell
- TRAP
- tartrate-resistant acid phosphatase
- CaR
- calcium-sensing receptor
- RANKL
- receptor activator of nuclear factor-κB ligand
- HP
- hydroxylysylpyridinoline
- MTT
- 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide
- β-Gal
- β-galactosidase cDNA
- siRNA
- small interfering RNA
- FCS
- fetal calf serum
- PS
- penicillin/streptomycin
- PBS
- phosphate-buffered saline
- DN
- dominant-negative
- PE
- phosphatidylethanolamine
- NF-κB
- nuclear factor-κB
- AP-1
- activator protein-1
- ELISA
- enzyme-linked immunosorbent assay
- OCL
- osteoclast-like cell
- M-CSF
- macrophage colony-stimulating factor.
- Received December 28, 2009.
- Accepted June 28, 2010.
- Copyright © 2010 The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|